Response Biomedical specializes in advanced acute care diagnostic technologies, primarily through its RAMP (Rapid Assessment of Multiple Parameters) systems. These systems are designed to deliver lab-quality results in a matter of minutes, enabling healthcare professionals to make timely and informed decisions. The RAMP platform supports a variety of tests, including those for cardiovascular conditions, infectious diseases, sepsis, women's health, arboviruses, and biodefense. Its ability to conduct parallel testing allows for up to six different tests to be run simultaneously, which is crucial in urgent care settings where time is of the essence.

The RAMP technology is characterized by its self-calibrating nature and resilience to environmental factors such as vibration, ensuring consistent and reliable performance. Additionally, the systems are designed for ease of use, requiring minimal maintenance and no service contracts, which contributes to a more efficient workflow in clinical environments. By reducing turnaround times and the need for retests, Response Biomedical's solutions not only enhance diagnostic accuracy but also help lower overall healthcare costs, making them a valuable asset in acute care diagnostics.

Canada

Response Biomedical Corp. develops, manufactures and markets the RAMP® system, a rapid diagnostics platform that delivers lab quality performance for efficient patient management in acute care settings. RAMP® is a global leader in comprehensive acute care testing with a wide range of markers available including Troponin I, CK-MB, Myoglobin, NT-proBNP, D-dimer and Procalcitonin. For effective and efficient patient care, RAMP® tests aid in the diagnosis of Acute Myocardial Infarction, Heart Failure and Sepsis.

Response Biomedical

Company Details